FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmacological industry, namely a preparation containing a prebiotic mixture and a probiotic bacterial strain. The preparation containing the prebiotic mixture comprising at least one N-acetylated oligosaccharide specified in a group: GalNAcα1,3Ga1β1,4G1c and Ga1β1,6Ga1NAcα1,3Ga1β1,4G1c; at least one neutral oligosaccharide specified in a group: Ga1β1,6Ga1,Ga1β1,6Ga1β1,4G1c Ga1β1,6Ga1β1,6G1c, Ga1β1,3Ga1β1,3G1c, Ga1β1,3Ga1β1,4Glc,Ga1β1,6Ga1β1,6Ga1β1,4G1c, Ga1β1,6Ga1β1,3Ga1β1,4G1c, Ga1β1,3Ga1β1,6Ga1β1,4G1c; and Ga1β1,3Ga1β1,3Ga1β1,4G1c; and at least one sialylated oligosaccharide specified in a group: NeuAcα2,3Ga1β1,4G1c and NeuAcα2,6Ga1β1,4G1c, and the probiotic bacterial strain specified in the strain Lactobacillus or the strain Bifidobacterium taken in certain proportions. A foodstuff containing the preparation. Using the preparation for making a therapeutic nutritional composition or a drug preparation (versions).
EFFECT: preparation shows high survival of the bifidogenic intestinal microbiota in nursing infants, enables higher relative metabolic activity of various types of bifidus bacteria.
17 cl, 6 dwg, 1 tbl, 6 ex
